FHIR IG analytics| Package | de.medizininformatikinitiative.kerndatensatz.onkologie |
| Resource Type | CarePlan |
| Id | CarePlan-mii-exa-onko-tumorkonferenz-molekular.json |
| FHIR Version | R4 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
English
Generated Narrative: CarePlan mii-exa-onko-tumorkonferenz-molekular
Profile: MII PR Onkologie Tumorkonferenz version: 2027.0.0-ballot.1
status: Active
intent: Plan
category: Molekulares Tumorboard
subject: Erika Beispiel Female, DoB: 1965-04-12
created: 2024-01-15
addresses: Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet
activity
Details
Code Status Description Zielgerichtete Anti-HER2 Therapie Not Started Basierend auf HER2-Amplifikation: Trastuzumab + Pertuzumab Kombination empfohlen
activity
Details
Code Status Description Chemotherapie + CDK4/6 Inhibitor Not Started Alternative basierend auf HR+/HER2- Status: Palbociclib + Letrozol
activity
Details
Code Status Description Strahlentherapie Not Started Adjuvante Bestrahlung nach Operation
German
Generated Narrative: CarePlan mii-exa-onko-tumorkonferenz-molekular
Profile: MII PR Onkologie Tumorkonferenz version: 2027.0.0-ballot.1
status: Active
intent: Plan
category: Molekulares Tumorboard
subject: Erika Beispiel Female, DoB: 1965-04-12
created: 2024-01-15
addresses: Condition Bösartige Neubildung: Brustdrüse, nicht näher bezeichnet
activity
Details
Code Status Description Zielgerichtete Anti-HER2 Therapie Not Started Basierend auf HER2-Amplifikation: Trastuzumab + Pertuzumab Kombination empfohlen
activity
Details
Code Status Description Chemotherapie + CDK4/6 Inhibitor Not Started Alternative basierend auf HR+/HER2- Status: Palbociclib + Letrozol
activity
Details
Code Status Description Strahlentherapie Not Started Adjuvante Bestrahlung nach Operation
{
"resourceType": "CarePlan",
"id": "mii-exa-onko-tumorkonferenz-molekular",
"meta": {
"profile": [
"https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/StructureDefinition/mii-pr-onko-tumorkonferenz|2027.0.0-ballot.1"
]
},
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"status": "active",
"intent": "plan",
"category": [
{
"coding": [
{
"system": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapieplanung-typ",
"code": "praeth"
}
],
"text": "Molekulares Tumorboard"
}
],
"subject": {
"reference": "Patient/example"
},
"created": "2024-01-15",
"addresses": [
{
"reference": "Condition/primaertumor-example"
}
],
"activity": [
{
"detail": {
"code": {
"coding": [
{
"system": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
"code": "ZS"
}
],
"text": "Zielgerichtete Anti-HER2 Therapie"
},
"status": "not-started",
"description": "Basierend auf HER2-Amplifikation: Trastuzumab + Pertuzumab Kombination empfohlen"
}
},
{
"detail": {
"code": {
"coding": [
{
"system": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
"code": "CZ"
}
],
"text": "Chemotherapie + CDK4/6 Inhibitor"
},
"status": "not-started",
"description": "Alternative basierend auf HR+/HER2- Status: Palbociclib + Letrozol"
}
},
{
"detail": {
"code": {
"coding": [
{
"system": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/CodeSystem/mii-cs-onko-therapie-typ",
"code": "ST"
}
],
"text": "Strahlentherapie"
},
"status": "not-started",
"description": "Adjuvante Bestrahlung nach Operation"
}
}
]
}